Related Experiment Video

Updated: Jul 11, 2025

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

7.7K

Role of c-Myc in lung cancer: Progress, challenges, and prospects

Nicholas J Wallbillich1,2, Hua Lu1,2

  • 1Department of Biochemistry and Molecular Biology, Tulane University School of Medicine, 1430 Tulane Avenue, New Orleans, LA 70112, USA.

Chinese Medical Journal Pulmonary and Critical Care Medicine
|November 3, 2023
PubMed

Insights

Targeting c-Myc, a key oncoprotein, offers a promising strategy to overcome therapeutic resistance in lung cancer. This approach aims to mitigate cancer stemness, improving survival for non-small cell lung cancer patients.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Lung cancer is a leading cause of cancer mortality globally, with poor survival rates for non-small cell lung cancer (NSCLC).
  • Therapeutic resistance, both inherent and acquired, significantly hinders effective NSCLC treatment.
  • The oncoprotein c-Myc is implicated in cancer progression, metastasis, and chemoresistance across various cancer types.

Purpose of the Study:

  • To review the mechanisms by which c-Myc regulates cancer stemness.
  • To summarize c-Myc's role in drug resistance in lung cancer.
  • To provide an overview of therapeutic strategies targeting c-Myc for lung cancer treatment.

Main Methods:

  • Literature review of studies on c-Myc, cancer stemness, and drug resistance in lung cancer.
  • Analysis of the role of c-Myc in regulating stemness genes.
  • Examination of current and future therapeutic approaches targeting c-Myc.

Main Results:

  • c-Myc overexpression is common in NSCLC and amplification occurs in small cell lung cancer (SCLC).
  • c-Myc directly regulates genes associated with cancer stemness, promoting tumor progression and therapeutic resistance.
  • Targeting c-Myc presents a potential strategy to overcome drug resistance in both SCLC and NSCLC.

Conclusions:

  • c-Myc plays a critical role in driving lung cancer stemness and therapeutic resistance.
  • Targeting c-Myc, directly or indirectly, is a promising avenue for developing novel lung cancer therapies.
  • Further research into c-Myc-targeted strategies could significantly improve outcomes for lung cancer patients.
Keywords:
Cancer dormancyCancer stem cellsDrug resistanceEpidermal growth factor receptorLung cancerNon-small cell lung cancerSmall cell lung cancerc-Myc

More Related Videos

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants07:39

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

122
Combined Use of Tail Vein Metastasis Assays and Real-Time In Vivo Imaging to Quantify Breast Cancer Metastatic Colonization and Burden in the Lungs10:32

Combined Use of Tail Vein Metastasis Assays and Real-Time In Vivo Imaging to Quantify Breast Cancer Metastatic Colonization and Burden in the Lungs

Published on: December 19, 2019

10.9K

Related Concept Videos

Induced Pluripotent Stem Cells01:06

Induced Pluripotent Stem Cells

Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
4.1K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
8.9K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K
Cancers Originate from Somatic Mutations in a Single Cell02:21

Cancers Originate from Somatic Mutations in a Single Cell

Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
12.0K